ROSGQ (Rosetta Genomics) Cyclically Adjusted PS Ratio: (As of Jul. 12, 2026)

Rosetta Genomics  (OTCPK:ROSGQ) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.

Rosetta Genomics Cyclically Adjusted PS Ratio Related Terms

The historical data trend for Rosetta Genomics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rosetta Genomics Cyclically Adjusted PS Ratio Chart

Rosetta Genomics Annual Data
	Trend	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16
Cyclically Adjusted PS Ratio		Get a 7-Day Free Trial					0.00	0.00	0.00	0.00	0.00

Rosetta Genomics Semi-Annual Data
	Dec07	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17
Cyclically Adjusted PS Ratio	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

ROSGQ vs TEAR, IDTA, ABMC: Cyclically Adjusted PS Ratio Comparison

For the Diagnostics & Research subindustry, Rosetta Genomics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rosetta Genomics Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Rosetta Genomics's Cyclically Adjusted PS Ratio falls into.

Rosetta Genomics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Rosetta Genomics's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec16 is calculated as:

For example, Rosetta Genomics's adjusted Revenue per Share data for the fiscal year that ended in Dec16 was:

Current CPI (Dec16) = 241.4320.

Rosetta Genomics Annual Data

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Rosetta Genomics Business Description